Where Do Bone-Targeted Agents RANK in Breast Cancer Treatment?

1049 RANKL pathway proteins as risk parameters for biochemical recurrence in patients undergoing radical prostatectomy

(2013) T. Todenhöfer et al.   EUROPEAN UROLOGY SUPPLEMENTS

Progesterone/RANKL Is a Major Regulatory Axis in the Human Breast

(2013) T. Tanos et al.   Science Translational Medicine

The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis

(2012) P. Hadji et al.   ANNALS OF ONCOLOGY

Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study

(2012) G. V. Scagliotti et al.   ANNALS OF ONCOLOGY

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

(2012) R. Coleman et al.   ANNALS OF ONCOLOGY

Pain outcomes in patients with advanced breast cancer and bone metastases

(2012) Charles S. Cleeland et al.   CANCER

S1-2: Long-Term Follow-Up in ABCSG-12: Significantly Improved Overall Survival with Adjuvant Zoledronic Acid in Premenopausal Patients with Endocrine-Receptor–Positive Early Breast Cancer.

(2012) M Gnant et al.   CANCER RESEARCH

RANK Induces Epithelial-Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis

(2012) M. Palafox et al.   CANCER RESEARCH

Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling

(2012) Hatem A. Azim et al.   CLINICAL CANCER RESEARCH

Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid

(2012) M. Martin et al.   CLINICAL CANCER RESEARCH

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

(2012) Allan Lipton et al.   EUROPEAN JOURNAL OF CANCER

Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study

(2012) Giorgio Vittorio Scagliotti et al.   Journal of Thoracic Oncology

Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial

(2012) Alexander HG Paterson et al.   LANCET ONCOLOGY

Comparison of distribution characteristics of metastatic bone lesions between breast and prostate carcinomas

(2012) CHANG-YIN WANG et al.   Oncology Letters

Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999–2006

(2011) Nalini Sathiakumar et al.   BREAST CANCER RESEARCH AND TREATMENT

Molecular Pathways: Osteoclast-Dependent and Osteoclast-Independent Roles of the RANKL/RANK/OPG Pathway in Tumorigenesis and Metastasis

(2011) W. C. Dougall   CLINICAL CANCER RESEARCH

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

(2011) David H. Henry et al.   JOURNAL OF CLINICAL ONCOLOGY

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

(2011) Karim Fizazi et al.   LANCET

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

(2011) Matthew R Smith et al.   LANCET

From the ranks of mammary progesterone mediators, RANKL takes the spotlight

(2011) Rodrigo Fernandez-Valdivia et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Breast-Cancer Adjuvant Therapy with Zoledronic Acid

(2011) Robert E. Coleman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients

(2011) Daniele Santini et al.   PLoS One

Denosumab and bisphosphonates: Different mechanisms of action and effects

(2010) Roland Baron et al.   BONE

Impact of Zoledronic Acid in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST.:

(2010) R. Coleman et al.   CANCER RESEARCH

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

(2010) Alison T. Stopeck et al.   JOURNAL OF CLINICAL ONCOLOGY

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis

(2010) Eva Gonzalez-Suarez et al.   NATURE

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer

(2010) Daniel Schramek et al.   NATURE

Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland

(2010) M. Beleut et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease

(2008) Ann E. Kearns et al.   ENDOCRINE REVIEWS

Impact of skeletal complications on patients’ quality of life, mobility, and functional independence

(2008) Luis Costa et al.   SUPPORTIVE CARE IN CANCER